Bladder cancer is a common urologic malignancy with rising incidence in the elderly population.
In most cases, bladder cancer is non-muscle-invasive at diagnosis and shows dramatically high recurrence rates, although current treatments often reduce the risk of disease progression. Immunotherapy using intravesical instillation of Bacillus Calmette-Guérin (BCG) remains the most effective therapy for patients with high risk tumors. However, BCG-therapy has important limitations including substantial adverse events and frequent treatment failure. Thus, it appears crucial to either improve or replace current therapy using new immunotherapeutic strategies. Here, we discuss the clinical trials that assessed therapeutic vaccination of bladder cancer patients using tumor associated antigens and we also argue for novel approaches arising from murine models. Vaccination routes to induce appropriate T-cell homing in the tumor site as well as the use of local immunostimulation to enhance recruitment of vaccine-induced T cells are discussed to highlight what we believe is a promising therapeutic vaccination strategy for patients with non-muscle-invasive bladder cancer.
Written by:
Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L. Are you the author?
Department of Urology; Centre Hospitalier Universitaire Vaudois and University of Lausanne; Lausanne, Switzerland.
Reference: Hum Vaccin Immunother. 2014 Jan 2;10(4).
PubMed Abstract
PMID: 24384699
UroToday.com Bladder Cancer Section
